During the past decade, St Apotheek der Haarlemse Ziekenhuizen conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "St Apotheek der Haarlemse Ziekenhuizen" are "Renal Cell Cancer" (1 trials) and "Urothelial Cancer" (1 trials). Many other conditions were trialed in "St Apotheek der Haarlemse Ziekenhuizen" in a lesser frequency.

Most popular intervention types in "St Apotheek der Haarlemse Ziekenhuizen" are "Biological" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (1 trials), "Avelumab (MSB0010718C)" (1 trials), "Axitinib (AG-013736)" (1 trials), "Best Supportive Care" (1 trials) and "Following the planned interim analysis for this study: Avelumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "St Apotheek der Haarlemse Ziekenhuizen" are 2 trials for "All" genders.

Currently, there are NaN active trials in "St Apotheek der Haarlemse Ziekenhuizen". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in St Apotheek der Haarlemse Ziekenhuizen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in St Apotheek der Haarlemse Ziekenhuizen, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".